Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 6Glioblastoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Phase IB 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Mesonephric Gynecologic Cancer 1Melanoma 1Lung Neoplasms 1Low-Grade Serous Ovarian Cancer 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Brain Neoplasms 1Advanced Colorectal Cancer 1Adenocarcinoma of Lung 1

Interventions

Oxaliplatin 3regorafenib 2Irinotecan 2Drug Therapy 2Cetuximab 2Capecitabine 2trifluridine tipiracil drug combination 1surufatinib 1raltitrexed 1paclitaxel poliglumex 1nimotuzumab 1endostar protein 1durvalumab 1defactinib 1aflibercept 1Panitumumab 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Colorectal Cancer × defactinib × Clear all
NCT06369259 2026-05-20

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡